Your browser doesn't support javascript.
loading
Plasma Exchange in Anti-Signal Recognition Particle Myopathy: A Systematic Review and Combined Analysis of Patient Individual Data.
Martínez-Rodríguez, Pablo; Escribano-Iglesias, María; Crisolino-Pozas, Ángel-P; Cubino-Boveda, Noelia; López-Parra, Miriam; Marcos, Miguel; Chamorro, Antonio-J.
Afiliación
  • Martínez-Rodríguez P; Connective Tissue Diseases Unit, Department of Internal Medicine, University Hospital of Salamanca-IBSAL, 37001 Salamanca, Spain.
  • Escribano-Iglesias M; Department of Medicine, Faculty of Medicine, University of Salamanca, 37001 Salamanca, Spain.
  • Crisolino-Pozas ÁP; Department of Radiology, University Hospital of Salamanca-IBSAL, 37001 Salamanca, Spain.
  • Cubino-Boveda N; Connective Tissue Diseases Unit, Department of Internal Medicine, University Hospital of Salamanca-IBSAL, 37001 Salamanca, Spain.
  • López-Parra M; Connective Tissue Diseases Unit, Department of Internal Medicine, University Hospital of Salamanca-IBSAL, 37001 Salamanca, Spain.
  • Marcos M; Department of Medicine, Faculty of Medicine, University of Salamanca, 37001 Salamanca, Spain.
  • Chamorro AJ; Department of Hematology, University Hospital of Salamanca-IBSAL, 37001 Salamanca, Spain.
J Pers Med ; 14(5)2024 Apr 27.
Article en En | MEDLINE | ID: mdl-38793043
ABSTRACT
Anti-signal recognition particle myopathy (anti-SRP myopathy) is a rare subtype of immune-mediated inflammatory myopathy characterized by muscle weakness and anti-SRP autoantibodies. Although plasma exchange (PE) is used in severe cases, its role remains unclear. A systematic review was conducted following PRISMA guidelines, identifying 23 patients with anti-SRP myopathy treated with PE. Data on demographics, clinical features, laboratory findings, treatments, and outcomes were analyzed combining individual patient data if available. Sixteen (69.6%) patients were male, with muscle weakness as the predominant symptom in 100% of cases. After PE, most patients showed improvement in symptoms, and the proportion of patients with muscle weakness was reduced (p = 0.001). Relapse occurred in 17.4% of the cases. The incidence of adverse events was low (8.7%). Despite limitations, including a small sample size and heterogeneous data, our systematic review suggests that PE may be effective in inducing remission and controlling symptoms in anti-SRP myopathy, particularly in severe cases. Since evidence on PE in anti-SRP myopathy is limited, further research, including prospective multicenter studies, is warranted to understand better its efficacy and safety and establish its role in treatment algorithms.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2024 Tipo del documento: Article País de afiliación: España